Since WT-FLT3 is sensitive to FL and is affected negligibly by FLT3 inhibitors, FL secretion in the bone marrow microenvironment leads to the activation of the FLT3/MAPK pathway and provides survival signals to AML cells during induction and consolidation therapy. This evidence concerns the gene FLT3 and acute myeloid leukemia.